[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f1S0Vwa5In8vPHzqhEWAMFeTyA2j-yr3zr107MdtBo1E":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"Children's Hospital of Eastern Ontario",[4],83,false,13,6,29358,3,64,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Type 1 Diabetes",5,{"name":18,"count":19},"Pain",4,{"name":21,"count":11},"Diabetes Mellitus, Type 1",{"name":23,"count":11},"Concussions",{"name":25,"count":11},"Asthma",{"name":27,"count":11},"Inflammatory Bowel Diseases",{"name":29,"count":11},"Crohn Disease",{"name":31,"count":32},"Obesity",2,[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06366334","Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation","2024-05-29","Ketamine Hydrochloride",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT01344200","CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children","2026-01-31","Celecoxib",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,77,101,119,145,171,196,214,250,276,301,332,350,368,386,404,422,440,466,505,533,559,585,609,636,654],{"intervention":43,"totalTrials":53,"cells":54},1,{"EARLY_PHASE1":55,"PHASE1":58,"PHASE2":60,"PHASE3":71,"PHASE4":73,"NA":75},{"trials":56,"activeCount":57},[],0,{"trials":59,"activeCount":57},[],{"trials":61,"activeCount":53,"soonestReadout":42},[62],{"nctId":40,"briefTitle":41,"status":63,"phases":64,"primaryCompletion":42,"completion":65,"start":66,"enrollment":67,"conditions":68,"interventions":70},"RECRUITING",[47],"2027-02-01","2024-01-29",65,[69],"Pharmacokinetics of Celecoxib in Children",[43],{"trials":72,"activeCount":57},[],{"trials":74,"activeCount":57},[],{"trials":76,"activeCount":57},[],{"intervention":38,"totalTrials":53,"cells":78},{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":87,"NA":89},{"trials":80,"activeCount":57},[],{"trials":82,"activeCount":57},[],{"trials":84,"activeCount":57},[],{"trials":86,"activeCount":57},[],{"trials":88,"activeCount":57},[],{"trials":90,"activeCount":53,"soonestReadout":37},[91],{"nctId":35,"briefTitle":36,"status":63,"phases":92,"primaryCompletion":37,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":99},[50],"2024-06-28","2024-01-15",20,[97,98],"Suicidal Ideation","Suicidal Ideas",[38,100],"Normal saline",{"intervention":100,"totalTrials":53,"cells":102},{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":109,"PHASE4":111,"NA":113},{"trials":104,"activeCount":57},[],{"trials":106,"activeCount":57},[],{"trials":108,"activeCount":57},[],{"trials":110,"activeCount":57},[],{"trials":112,"activeCount":57},[],{"trials":114,"activeCount":53,"soonestReadout":37},[115],{"nctId":35,"briefTitle":36,"status":63,"phases":116,"primaryCompletion":37,"completion":93,"start":94,"enrollment":95,"conditions":117,"interventions":118},[50],[97,98],[38,100],{"intervention":120,"totalTrials":53,"cells":121},"24% sucrose po solution",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":143},{"trials":123,"activeCount":57},[],{"trials":125,"activeCount":57},[],{"trials":127,"activeCount":57},[],{"trials":129,"activeCount":57},[],{"trials":131,"activeCount":57},[132],{"nctId":133,"briefTitle":134,"status":135,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":142},"NCT01438008","Pilot Study of Sucrose to Reduce Pain in Sick Babies","TERMINATED",[49],"2016-09","2012-05",9,[141],"Pain Due to Certain Specified Procedures",[120],{"trials":144,"activeCount":57},[],{"intervention":146,"totalTrials":53,"cells":147},"Hydrocortisone",{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":169},{"trials":149,"activeCount":57},[],{"trials":151,"activeCount":57},[],{"trials":153,"activeCount":57},[],{"trials":155,"activeCount":57},[],{"trials":157,"activeCount":57},[158],{"nctId":159,"briefTitle":160,"status":161,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":168},"NCT02044159","Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study","COMPLETED",[49],"2016-04","2014-07",57,[167],"Shock",[146],{"trials":170,"activeCount":57},[],{"intervention":172,"totalTrials":53,"cells":173},"24% sucrose",{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":194},{"trials":175,"activeCount":57},[],{"trials":177,"activeCount":57},[],{"trials":179,"activeCount":57},[],{"trials":181,"activeCount":57},[],{"trials":183,"activeCount":57},[184],{"nctId":185,"briefTitle":186,"status":135,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":192},"NCT02151136","Be Sweet to Toddlers: Does Sugar Water Reduce Pain During Blood Work?",[49],"2019-07","2015-11",86,[141],[172,193],"Sterile water",{"trials":195,"activeCount":57},[],{"intervention":193,"totalTrials":53,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":212},{"trials":199,"activeCount":57},[],{"trials":201,"activeCount":57},[],{"trials":203,"activeCount":57},[],{"trials":205,"activeCount":57},[],{"trials":207,"activeCount":57},[208],{"nctId":185,"briefTitle":186,"status":135,"phases":209,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":210,"interventions":211},[49],[141],[172,193],{"trials":213,"activeCount":57},[],{"intervention":215,"totalTrials":32,"cells":216},"Dexamethasone",{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":246,"NA":248},{"trials":218,"activeCount":57},[],{"trials":220,"activeCount":57},[],{"trials":222,"activeCount":57},[],{"trials":224,"activeCount":57},[225,236],{"nctId":226,"briefTitle":227,"status":161,"phases":228,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT02794441","Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in the Pediatric Emergency Department",[48],"2017-06","2017-06-28","2016-12",12,[234],"Migraine",[215],{"nctId":237,"briefTitle":238,"status":135,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":95,"conditions":243,"interventions":244},"NCT03133897","Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study",[48],"2019-08-02","2020-03-11","2018-03-05",[25],[215,245],"Prednisone",{"trials":247,"activeCount":57},[],{"trials":249,"activeCount":57},[],{"intervention":251,"totalTrials":53,"cells":252},"MPH",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":272,"NA":274},{"trials":254,"activeCount":57},[],{"trials":256,"activeCount":57},[],{"trials":258,"activeCount":57},[],{"trials":260,"activeCount":57},[261],{"nctId":262,"briefTitle":263,"status":264,"phases":265,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":271},"NCT02754258","The Effects of Methylphenidate on Energy Intake and Energy Expenditure","UNKNOWN",[48],"2018-08","2018-12","2017-01",40,[31],[251],{"trials":273,"activeCount":57},[],{"trials":275,"activeCount":57},[],{"intervention":277,"totalTrials":53,"cells":278},"Cholecalciferol",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":297,"NA":299},{"trials":280,"activeCount":57},[],{"trials":282,"activeCount":57},[],{"trials":284,"activeCount":57},[],{"trials":286,"activeCount":57},[287],{"nctId":288,"briefTitle":289,"status":161,"phases":290,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":296},"NCT03742505","Rapid Normalization of Vitamin D Deficiency in PICU",[48],"2024-10-17","2019-06-17",424,[295],"Vitamin D Deficiency",[277],{"trials":298,"activeCount":57},[],{"trials":300,"activeCount":57},[],{"intervention":302,"totalTrials":53,"cells":303},"Oral dexamethasone",{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":328,"NA":330},{"trials":305,"activeCount":57},[],{"trials":307,"activeCount":57},[],{"trials":309,"activeCount":57},[],{"trials":311,"activeCount":57},[312],{"nctId":313,"briefTitle":314,"status":161,"phases":315,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":322},"NCT03567473","Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study",[48],"2025-01-07","2025-05-21","2018-12-13",864,[321],"Bronchiolitis",[302,323,324,325,326,327],"Nebulized Epinephrine","Oral placebo","Nebulized normal saline","MDI Epinephrine","MDI placebo",{"trials":329,"activeCount":57},[],{"trials":331,"activeCount":57},[],{"intervention":323,"totalTrials":53,"cells":333},{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":338,"PHASE3":340,"PHASE4":346,"NA":348},{"trials":335,"activeCount":57},[],{"trials":337,"activeCount":57},[],{"trials":339,"activeCount":57},[],{"trials":341,"activeCount":57},[342],{"nctId":313,"briefTitle":314,"status":161,"phases":343,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":344,"interventions":345},[48],[321],[302,323,324,325,326,327],{"trials":347,"activeCount":57},[],{"trials":349,"activeCount":57},[],{"intervention":324,"totalTrials":53,"cells":351},{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":364,"NA":366},{"trials":353,"activeCount":57},[],{"trials":355,"activeCount":57},[],{"trials":357,"activeCount":57},[],{"trials":359,"activeCount":57},[360],{"nctId":313,"briefTitle":314,"status":161,"phases":361,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":362,"interventions":363},[48],[321],[302,323,324,325,326,327],{"trials":365,"activeCount":57},[],{"trials":367,"activeCount":57},[],{"intervention":325,"totalTrials":53,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":382,"NA":384},{"trials":371,"activeCount":57},[],{"trials":373,"activeCount":57},[],{"trials":375,"activeCount":57},[],{"trials":377,"activeCount":57},[378],{"nctId":313,"briefTitle":314,"status":161,"phases":379,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":380,"interventions":381},[48],[321],[302,323,324,325,326,327],{"trials":383,"activeCount":57},[],{"trials":385,"activeCount":57},[],{"intervention":326,"totalTrials":53,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":400,"NA":402},{"trials":389,"activeCount":57},[],{"trials":391,"activeCount":57},[],{"trials":393,"activeCount":57},[],{"trials":395,"activeCount":57},[396],{"nctId":313,"briefTitle":314,"status":161,"phases":397,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":398,"interventions":399},[48],[321],[302,323,324,325,326,327],{"trials":401,"activeCount":57},[],{"trials":403,"activeCount":57},[],{"intervention":327,"totalTrials":53,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":418,"NA":420},{"trials":407,"activeCount":57},[],{"trials":409,"activeCount":57},[],{"trials":411,"activeCount":57},[],{"trials":413,"activeCount":57},[414],{"nctId":313,"briefTitle":314,"status":161,"phases":415,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":416,"interventions":417},[48],[321],[302,323,324,325,326,327],{"trials":419,"activeCount":57},[],{"trials":421,"activeCount":57},[],{"intervention":245,"totalTrials":53,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":436,"NA":438},{"trials":425,"activeCount":57},[],{"trials":427,"activeCount":57},[],{"trials":429,"activeCount":57},[],{"trials":431,"activeCount":57},[432],{"nctId":237,"briefTitle":238,"status":135,"phases":433,"primaryCompletion":240,"completion":241,"start":242,"enrollment":95,"conditions":434,"interventions":435},[48],[25],[215,245],{"trials":437,"activeCount":57},[],{"trials":439,"activeCount":57},[],{"intervention":441,"totalTrials":53,"cells":442},"Olanzapine",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":462,"NA":464},{"trials":444,"activeCount":57},[],{"trials":446,"activeCount":57},[],{"trials":448,"activeCount":57},[],{"trials":450,"activeCount":57},[451],{"nctId":452,"briefTitle":453,"status":135,"phases":454,"primaryCompletion":455,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":461},"NCT01184443","Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents",[48],"2013-08","2014-03","2010-08",38,[460],"Eating Disorder",[441],{"trials":463,"activeCount":57},[],{"trials":465,"activeCount":57},[],{"intervention":467,"totalTrials":32,"cells":468},"Zoledronic acid",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":470,"activeCount":57},[],{"trials":472,"activeCount":57},[],{"trials":474,"activeCount":57},[475,488],{"nctId":476,"briefTitle":477,"status":478,"phases":479,"primaryCompletion":480,"completion":481,"start":482,"enrollment":57,"conditions":483,"interventions":487},"NCT02632903","Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study","WITHDRAWN",[47],"2018-03","2018-08-20","2016-10",[484,485,486],"Osteoporosis","Osteonecrosis","Acute Lymphoblastic Leukemia",[467],{"nctId":489,"briefTitle":490,"status":161,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":496},"NCT02632916","Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study",[47],"2020-02-03","2016-08",10,[484],[497,498],"Zoledronic Acid","Denosumab",{"trials":500,"activeCount":57},[],{"trials":502,"activeCount":57},[],{"trials":504,"activeCount":57},[],{"intervention":506,"totalTrials":53,"cells":507},"Celebrex suspension",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":509,"activeCount":57},[],{"trials":511,"activeCount":57},[],{"trials":513,"activeCount":57},[514],{"nctId":515,"briefTitle":516,"status":161,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":526},"NCT00849966","Celecoxib for Pediatric Adenotonsillectomy",[47],"2012-08","2012-12","2009-08",282,[523,524,525],"Tonsillectomy","Adenotonsillectomy","Pain, Postoperative",[506],{"trials":528,"activeCount":57},[],{"trials":530,"activeCount":57},[],{"trials":532,"activeCount":57},[],{"intervention":534,"totalTrials":53,"cells":535},"Vitamin D3",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":537,"activeCount":57},[],{"trials":539,"activeCount":57},[],{"trials":541,"activeCount":57},[542],{"nctId":543,"briefTitle":544,"status":161,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT02452762","Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial",[47],"2017-11","2018-01","2016-01",67,[551],"Hypovitaminosis D",[534],{"trials":554,"activeCount":57},[],{"trials":556,"activeCount":57},[],{"trials":558,"activeCount":57},[],{"intervention":560,"totalTrials":53,"cells":561},"LET - Lidocaine Epinephrine Tetracaine",{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":563,"activeCount":57},[],{"trials":565,"activeCount":57},[],{"trials":567,"activeCount":57},[568],{"nctId":569,"briefTitle":570,"status":161,"phases":571,"primaryCompletion":572,"completion":573,"start":574,"enrollment":575,"conditions":576,"interventions":578},"NCT01202487","Gluing Lacerations Utilizing Epinephrine",[47],"2012-01","2012-04","2011-04",222,[577],"Lacerations",[560],{"trials":580,"activeCount":57},[],{"trials":582,"activeCount":57},[],{"trials":584,"activeCount":57},[],{"intervention":586,"totalTrials":53,"cells":587},"Twice Daily versus Three Times Daily Insulin Injections",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":589,"activeCount":57},[],{"trials":591,"activeCount":57},[],{"trials":593,"activeCount":57},[594],{"nctId":595,"briefTitle":596,"status":161,"phases":597,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":602},"NCT00146484","A Study of Two Versus Three Daily Injections in Children and Adolescents With Newly Diagnosed Type 1 Diabetes",[47],"2001-01","1996-04",100,[21],[586],{"trials":604,"activeCount":57},[],{"trials":606,"activeCount":57},[],{"trials":608,"activeCount":57},[],{"intervention":610,"totalTrials":53,"cells":611},"clonidine",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":613,"activeCount":57},[],{"trials":615,"activeCount":57},[],{"trials":617,"activeCount":57},[618],{"nctId":619,"briefTitle":620,"status":161,"phases":621,"primaryCompletion":622,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":629},"NCT00130091","The Addition of Clonidine to 0.2% Ropivacaine for Wound Instillation After Minor Lower Abdominal Surgery in Children",[47],"2014-02","2014-12","2009-09",120,[627,628],"Hernia, Inguinal","Hydrocele",[610],{"trials":631,"activeCount":57},[],{"trials":633,"activeCount":57},[],{"trials":635,"activeCount":57},[],{"intervention":498,"totalTrials":53,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":639,"activeCount":57},[],{"trials":641,"activeCount":57},[],{"trials":643,"activeCount":57},[644],{"nctId":489,"briefTitle":490,"status":161,"phases":645,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":646,"interventions":647},[47],[484],[497,498],{"trials":649,"activeCount":57},[],{"trials":651,"activeCount":57},[],{"trials":653,"activeCount":57},[],{"intervention":655,"totalTrials":53,"cells":656},"Tocilizumab",{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":665,"NA":667},{"trials":658,"activeCount":57},[],{"trials":660,"activeCount":57},[],{"trials":662,"activeCount":57},[],{"trials":664,"activeCount":57},[],{"trials":666,"activeCount":57},[],{"trials":668,"activeCount":57},[669],{"nctId":670,"briefTitle":671,"status":161,"phases":672,"primaryCompletion":572,"completion":572,"start":673,"enrollment":53,"conditions":674,"interventions":676},"NCT01041248","Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab",[50],"2010-01",[675],"Relapsing Polychondritis",[655]]